AXGN - AxoGen Inc Stock Price, Fair Value and News

6.06USD+0.09 (+1.51%)Delayed

Market Summary

USD6.06+0.09

Delayed

1.51%

AXGN Alerts

Losses in recent quarter

AXGN Stock Price

View Fullscreen

AXGN RSI Chart

AXGN Valuation

Market Cap

264.8M

Price/Earnings (Trailing)

-12.45

Price/Sales (Trailing)

1.62

EV/EBITDA

-49.84

Price/Free Cashflow

-12.58

AXGN Price/Sales (Trailing)

AXGN Profitability

EBT Margin

-9.26%

Return on Equity

-22.84%

Return on Assets

-11.41%

Free Cashflow Yield

-7.95%

AXGN Fundamentals

AXGN Revenue

Revenue (TTM)

163.7M

Rev. Growth (Yr)

12.86%

Rev. Growth (Qtr)

-3.6%

AXGN Earnings

Earnings (TTM)

-21.3M

Earnings Growth (Yr)

6.21%

Earnings Growth (Qtr)

-70.43%

Breaking Down AXGN Revenue

Last 7 days

5.4%

Last 30 days

-12.7%

Last 90 days

-42.8%

Trailing 12 Months

-34.2%

How does AXGN drawdown profile look like?

AXGN Financial Health

Current Ratio

3.43

Debt/Equity

0.5

Debt/Cashflow

-0.23

AXGN Investor Care

Shares Dilution (1Y)

2.04%

Diluted EPS (TTM)

-0.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	163.7M	0	0	0
2023	144.2M	147.9M	152.3M	159.0M
2022	127.3M	128.2M	134.0M	138.6M
2021	119.1M	130.5M	128.3M	127.4M
2020	107.7M	103.1M	108.0M	112.3M
2019	90.0M	96.1M	102.0M	106.7M
2018	65.4M	70.9M	77.5M	83.9M
2017	45.2M	50.0M	54.9M	60.4M
2016	30.5M	34.5M	37.5M	41.1M
2015	18.6M	20.8M	24.3M	27.3M
2014	11.9M	13.3M	15.0M	16.8M
2013	8.2M	9.0M	10.0M	10.9M
2012	5.4M	6.2M	7.0M	7.7M
2011	3.5M	3.9M	4.4M	4.8M
2010	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AxoGen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	scopelianos angelo	acquired	-	-	2,500	chief r&d officer
Mar 21, 2024	donovan michael patrick	sold	-46,333	7.68	-6,033	vp operations
Mar 21, 2024	devinney erick wayne	sold	-35,159	7.68	-4,578	chief innovation officer
Mar 21, 2024	zaderej karen l.	sold	-301,670	7.68	-39,280	ceo
Mar 21, 2024	scopelianos angelo	sold	-52,846	7.68	-6,881	chief r&d officer
Mar 16, 2024	devinney erick wayne	acquired	-	-	18,675	chief innovation officer
Mar 16, 2024	donovan michael patrick	acquired	-	-	24,575	vp operations
Mar 16, 2024	zaderej karen l.	acquired	-	-	110,322	ceo
Mar 16, 2024	scopelianos angelo	acquired	-	-	25,406	chief r&d officer
Mar 07, 2024	donovan michael patrick	sold	-319,891	8.81	-36,310	vp operations

Which funds bought or sold AXGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-75.69	-368,181	148,399	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.29	-12,384	33,329	-%
May 15, 2024	Centiva Capital, LP	reduced	-55.69	-99,501	109,340	-%
May 15, 2024	UNITED CAPITAL FINANCIAL ADVISORS, LLC	reduced	-0.6	26,375	177,564	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-97.48	-77,979	2,389	-%
May 15, 2024	Quarry LP	added	70.29	6,864	13,646	-%
May 15, 2024	Divisadero Street Capital Management, LP	added	117	492,790	806,758	0.19%
May 15, 2024	ArrowMark Colorado Holdings LLC	reduced	-8.26	2,954,420	38,144,600	0.43%
May 15, 2024	SHERBROOKE PARK ADVISERS LLC	sold off	-100	-142,057	-	-%
May 15, 2024	First Light Asset Management, LLC	added	177	4,292,280	6,180,700	0.47%

Are Funds Buying or Selling AXGN?

Are funds buying AXGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXGN

No. of Funds

AXGN Alerts

Losses in recent quarter

Unveiling AxoGen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	arrowmark colorado holdings llc	11.97%	5,152,300	SC 13G/A
Feb 13, 2024	vanguard group inc	5.73%	2,465,496	SC 13G
Feb 12, 2024	morgan stanley	6.6%	2,859,421	SC 13G
Feb 02, 2024	soleus capital master fund, l.p.	6.0%	2,595,815	SC 13G/A
Jan 26, 2024	blackrock inc.	7.8%	3,342,773	SC 13G/A
Aug 11, 2023	soleus capital master fund, l.p.	8.2%	3,541,298	SC 13G
Aug 10, 2023	arrowmark colorado holdings llc	10.34%	4,431,629	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	4.3%	1,815,000	SC 13G/A
Feb 03, 2023	first light asset management, llc	4.59%	1,942,270	SC 13G
Jan 31, 2023	blackrock inc.	7.5%	3,159,410	SC 13G/A

Recent SEC filings of AxoGen Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 29, 2024	EFFECT	EFFECT
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 04, 2024	PRE 14A	PRE 14A
Mar 29, 2024	S-3/A	S-3/A
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to AxoGen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

AxoGen Inc News

Latest updates

AxoGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-3.6%	41,378,000	42,922,000	41,271,000	38,155,000	36,664,000	36,164,000	36,959,000	34,454,000	31,007,000	31,537,000	31,204,000	33,580,000	31,037,000	32,495,000	33,428,000	22,116,000	24,261,000	28,162,000	28,564,000	26,701,000	23,285,000
Gross Profit	-3.4%	32,620,000	33,764,000	33,228,000	30,927,000	29,955,000	30,023,000	30,783,000	28,170,000	25,461,000	26,109,000	25,965,000	26,488,000	25,865,000	27,032,000	27,731,000	16,511,000	19,445,000	23,281,000	24,054,000	22,457,000	19,571,000
Costs and Expenses	0.6%	37,180,000	36,958,000	37,253,000	37,829,000	37,296,000	35,631,000	35,638,000	36,094,000	36,781,000	31,462,000	32,654,000	33,642,000	32,085,000	32,406,000	28,776,000	24,765,000	27,954,000	30,700,000	30,166,000	30,129,000	29,774,000
S&GA Expenses	-10.6%	19,815,000	22,175,000	21,429,000	20,838,000	21,618,000	19,879,000	19,792,000	19,669,000	20,888,000	17,734,500	18,370,000	19,250,000	17,973,000	19,805,000	17,726,000	14,290,000	17,838,000	18,804,000	18,245,000	18,467,000	16,434,000
R&D Expenses	1.5%	7,409,000	7,301,500	6,989,000	7,363,000	6,679,000	6,811,000	7,050,000	7,022,000	6,275,000	6,302,000	6,404,000	5,723,000	5,748,000	4,931,000	4,230,000	4,071,000	4,614,000	4,912,000	4,181,000	4,282,000	4,139,000
EBITDA Margin	32.2%	-0.03	-0.05	-0.07	-0.08	-0.08	-0.08	-0.09	-0.09	-0.09	-0.09	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.2%	1,656,000	1,843,500	827,000	148,000	16,000	-40,000	61,000	249,000	354,000	-70,500	417,000	565,000	444,000	595,000	397,000	31,000	31,000	9,000	6,000	11,000	14,000
EBT Margin	2.9%	-0.09	-0.10	-0.10	-0.10	-0.11	-0.11	-0.11	-0.12	-0.12	-0.12	-	-	-	-	-	-	-	-	-	-	-
Net Income	-70.4%	-6,635,000	-3,893,000	-4,089,000	-6,660,000	-7,074,000	-5,415,000	-4,318,000	-7,740,000	-11,475,000	-5,286,000	-7,141,000	-7,898,000	-6,660,000	-6,010,000	-1,479,000	-8,105,000	-8,192,000	-7,038,000	-5,571,000	-7,022,000	-9,504,000
Net Income Margin	4.8%	-0.13	-0.14	-0.15	-0.16	-0.17	-0.21	-0.22	-0.25	-0.25	-0.21	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-687.9%	-13,190,000	-1,674,000	-2,064,000	-4,123,000	-11,727,000	-5,260,000	-5,059,000	-9,737,000	-16,088,000	-8,684,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.2%	187	197	195	192	189	195	196	196	198	208	210	211	197	201	194	170	145	155	154	157	160
Current Assets	-10.6%	79.00	88.00	87.00	86.00	89.00	98.00	102	107	112	127	135	142	135	145	140	140	120	135	137	141	146
Cash Equivalents	-30.0%	22.00	31.00	31.00	23.00	8.00	15.00	21.00	18.00	21.00	39.00	53.00	59.00	46.00	56.00	68.00	86.00	42.00	42.00	31.00	31.00	30.00
Inventory	20.1%	28.00	23.00	23.00	21.00	20.00	19.00	19.00	19.00	17.00	17.00	15.00	13.00	13.00	13.00	12.00	13.00	15.00	14.00	14.00	14.00	13.00
Net PPE	-	-	-	-	-	-	-	-	-	-	63.00	56.00	51.00	44.00	38.00	36.00	25.00	20.00	15.00	12.00	10.00	9.00
Liabilities	-7.7%	93.00	101	97.00	94.00	92.00	94.00	94.00	94.00	94.00	95.00	95.00	92.00	78.00	78.00	72.00	50.00	21.00	22.00	19.00	19.00	20.00
Current Liabilities	-24.6%	23.00	30.00	27.00	24.00	21.00	24.00	24.00	24.00	23.00	24.00	23.00	22.00	22.00	23.00	19.00	14.00	19.00	21.00	17.00	16.00	16.00
Long Term Debt	0.5%	47.00	47.00	46.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	46.00	46.00	32.00	32.00	32.00	32.00	1.00	-	2.00	2.00	3.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	1.00
LT Debt, Non Current	-100.0%	-	47.00	46.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	46.00	46.00	32.00	32.00	19.00	-	1.00	-	2.00	2.00	3.00
Shareholder's Equity	-2.6%	93.00	96.00	98.00	97.00	98.00	101	101	102	104	113	115	119	120	123	122	120	124	132	135	138	141
Retained Earnings	-2.4%	-287	-281	-277	-273	-266	-259	-254	-249	-242	-230	-225	-218	-210	-203	-197	-196	-188	-179	-172	-167	-160
Additional Paid-In Capital	1.1%	381	377	375	370	364	360	355	351	346	343	340	336	330	326	319	316	312	312	308	305	301
Shares Outstanding	1.3%	44.00	43.00	43.00	43.00	43.00	42.00	42.00	42.00	42.00	41.00	41.00	41.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	314	-	-	-	222	-	-	-	642	-	-	-	217	-	-	-	540	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-5713.3%	-12,266	-211	1,626	292	-7,423	1,362	-689	-5,688	-11,051	-1,514	-376	-695	-10,820	2,837	2,618	-7,029	-8,052	-3,330	-1,864	-5,811	-8,867
Share Based Compensation	195.3%	3,919	1,327	4,747	5,390	2,954	4,154	3,849	4,910	2,678	1,509	2,911	3,805	2,694	2,745	2,947	2,222	556	2,920	2,395	2,674	2,315
Cashflow From Investing	-1073.6%	-3,251	-277	5,994	14,322	-786	-1,209	2,971	2,279	-7,241	-13,585	-6,777	-4,157	870	-19,352	-21,130	14,969	8,550	13,586	921	4,994	7,770
Cashflow From Financing	-51.2%	204	418	5.00	898	633	813	215	671	95.00	1,043	805	18,087	517	4,515	191	36,096	-328	913	620	2,173	325
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	8.00	17.00	639	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AXGN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 41,378	$ 36,664
Cost of goods sold	8,758	8,172
Gross profit	32,620	28,492
Costs and expenses:
Sales and marketing	19,815	19,446
Research and development	7,409	6,326
General and administrative	9,956	10,061
Total costs and expenses	37,180	35,833
Loss from operations	(4,560)	(7,341)
Other income (expense):
Investment income	293	549
Interest expense	(2,326)	(16)
Change in fair value of derivatives	65	(185)
Other expense	(107)	(81)
Total other (expense) income, net	(2,075)	267
Net loss	$ (6,635)	$ (7,074)
Weighted average common shares outstanding - basic (in shares)	43,233,149	42,571,021
Weighted average common shares outstanding - diluted (in shares)	43,233,149	42,571,021
Loss per common share - basic (in USD per share)	$ (0.15)	$ (0.17)
Loss per common share - diluted (in USD per share)	$ (0.15)	$ (0.17)

AXGN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 15,713	$ 31,024
Restricted cash	6,000	6,002
Investments	1,921	0
Accounts receivable, net of allowance for doubtful accounts of $603 and $337, respectively	24,212	25,147
Inventory	27,636	23,020
Prepaid expenses and other	3,181	2,811
Total current assets	78,663	88,004
Property and equipment, net	87,838	88,730
Operating lease right-of-use assets	15,247	15,562
Intangible assets, net	4,768	4,531
Total assets	186,516	196,827
Current liabilities:
Accounts payable and accrued expenses	21,288	28,883
Current maturities of long-term lease obligations	1,644	1,547
Total current liabilities	22,932	30,430
Long-term debt, net of debt discount and financing fees	46,825	46,603
Long-term lease obligations	20,681	21,142
Debt derivative liabilities	2,922	2,987
Total liabilities	93,360	101,162
Commitments and contingencies - see Note 12
Shareholders’ equity:
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 43,687,729 and 43,124,496 shares issued and outstanding	437	431
Additional paid-in capital	380,650	376,530
Accumulated deficit	(287,931)	(281,296)
Total shareholders’ equity	93,156	95,665
Total liabilities and shareholders’ equity	$ 186,516	$ 196,827

About AxoGen Inc

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

CEO	Ms. Karen Zaderej
WEBSITE	axogeninc.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	394

AxoGen Inc Frequently Asked Questions

What is the ticker symbol for AxoGen Inc? What does AXGN stand for in stocks?

AXGN is the stock ticker symbol of AxoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AxoGen Inc (AXGN)?

As of Fri May 17 2024, market cap of AxoGen Inc is 264.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers. The fair value of AxoGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AxoGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AxoGen Inc a good stock to buy?

The fair value guage provides a quick view whether AXGN is over valued or under valued. Whether AxoGen Inc is cheap or expensive depends on the assumptions which impact AxoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXGN.

What is AxoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AXGN's PE ratio (Price to Earnings) is -12.45 and Price to Sales (PS) ratio is 1.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AxoGen Inc's stock?

In the past 10 years, AxoGen Inc has provided 0.091 (multiply by 100 for percentage) rate of return.